Mapping the Landscape: What We Know (and Don’t Know) About Reducing Cannabis Harms
This cannabis harm reduction strategies review maps existing interventions without assessing their effectiveness. It highlights the fragmented evidence base and the need for rigorous trials. Clinicians should focus on biologically plausible risk…
What Does the Evidence Really Say About Cannabis Risks and Medical Benefits?
The cannabis health risks medical benefits evidence review 2024 synthesizes global research on recreational cannabis harms and medicinal benefits. It highlights adolescent vulnerability and modest medicinal efficacy. This review guides clinicians on…
First Systematic Typology of Cannabis Harm Reduction Strategies Maps a Fragmented Field
This 2024 scoping review presents a cannabis harm reduction typology that classifies legal, organizational, and health-related strategies. It highlights the fragmented field and the lack of effectiveness data. The typology provides a foundation for…
Colorado: Data Finds No Evidence of Underage Cannabis Sales at Licensed Retailers
Colorado cannabis regulatory compliance data shows no evidence of underage cannabis sales at licensed retailers. This supports the effectiveness of state oversight in preventing direct retail access to minors. Clinicians should focus on secondary access…
Demographic Features, Health Status, and Behavioral Changes Associated with Cannabidiol Use in the Dog Aging Project
This study examines CBD use patterns companion dogs and their association with health status and behavioral changes. It provides valuable insights from the Dog Aging Project. Understanding these patterns helps inform clinical discussions about…
County to Invest in Communities Overly Impacted by Past Cannabis Enforcement
Social equity cannabis investments aim to improve healthcare access in communities disproportionately affected by past cannabis enforcement. These programs fund education and economic development to reduce health disparities. Clinicians should be aware…
Dr. Dan Brennan: Adolescent Cannabis Use and Rising Risk of Mental Health Disorders
Adolescent cannabis use mental health risk is a growing concern during critical neurodevelopmental periods. This association is vital for pediatric and family medicine practitioners. Understanding these risks aids in evidence-based counseling for…
Regulatory Digest 2026-03-10
Regulatory updates (higher clinical relevance)
Regulatory Digest 2026-03-09
Regulatory updates (higher clinical relevance)
Cannabinoid Clinical Trials: CBD and WADA Drug Testing
2026 cannabis clinical trials reveal that broad-spectrum CBD supplements can lead to detectable WADA-prohibited cannabinoids in urine. Exercise amplifies these concentrations, increasing doping risk. Athletes should be cautious with CBD products to avoid…